OA21.04 Amivantamab in Patients with Advanced NSCLC and MET Exon 14 Skipping Mutation: Results from the CHRYSALIS Study
N. Leighl, Byoung Chul Cho(Yonsei University), Sandrine Hiret(Institut de Cancérologie de l'Ouest), Ji‐Youn Han(National Cancer Center), Ki Hyeong Lee(Chungbuk National University Hospital), Casilda Llácer Pérez(Instituto de Investigación Biomédica de Málaga), Matthew Krebs(University of Manchester), Filippo de Braud(Fondazione IRCCS Istituto Nazionale dei Tumori), Eric B. Haura(Moffitt Cancer Center), Rachel E. Sanborn(Providence Portland Medical Center), J.C-H. Yang(National Taiwan University), Catherine A. Shu(Columbia University Irving Medical Center), Keiko Goto(National Cancer Center Hospital East), Makoto Nishio(Japanese Foundation For Cancer Research), J. Zhao(Peking University Cancer Hospital), Z. Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), P. Tomasini(Inserm), Enriqueta Felip(Vall d'Hebron Institute of Oncology), Jonathan W. Goldman(University of California, Los Angeles), S.‐H.I. Ou(University of California, Irvine), Michael Boyer(Chris O’Brien Lifehouse), Grace Gao(Janssen (Belgium)), Su Qu(Janssen (Belgium)), Joshua C. Curtin(Janssen (United States)), X. Lyu(Janssen (Belgium)), Amy Roshak(Janssen (United States)), R.W. Schnepp(Janssen (United States)), Philip Kim(Janssen (United States)), Jennifer A. Mertz(Janssen (United States)), Meena Thayu(Janssen (United States)), S. Martin Shreeve(Janssen (United States)), Roland E. Knoblauch(Janssen (United States)), Alexander I. Spira
Cited by 14Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis